At The Cutting Edge of Developments in the Management of Hyperkalemia

Slides:

Advertisements

Similar presentations

 Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney Disease:

Advertisements

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

~ Make a Difference ~ Become a Nephrology Nurse. Incidence (rate of occurrence) –220 per million in 1992 –334 per million in 2000 Prevalence (number of.

Pharmacologic Treatment of Chronic Systolic Heart Failure John N. Hamaty D.O. FACC, FACOI.

Anemia in Hemodialysis 1. 2 Etiology The anemia of chronic kidney disease (CKD) is primarily due to insufficient production of the glycoprotein hormone.

Manufacturer: Relypsa Inc. FDA Approval Date: October 21, 2015

The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.

Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease Department of Nephrology R3. Yeehyung Kim.

PATIROMER: A NEW POTASSIUM BINDING RESIN.

The EuLITE (Ongoing) Source

The EuLITE (Ongoing).

The IDEAL Study Reference

Prior Trials of RAAS Inhibitors

Emerging Concepts in Heart Failure

Current State of Hyperkalemia Management

Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,

Advancing Management of Anemia With the Latest Data From ERA-EDTA 2018

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

New and Emerging Management Options for Anemia in CKD

An Endocrinology Clinic in Dyslipidemia

PCP Perspectives Pathophysiologic Principles in the Management of Hyperkalemia.

Hyperkalemia in the Hospital: Collaboration to Improve Transitions of Care.

New Therapies for Hyperkalemia Across the Continuum of Care

Emerging Data on ACS Management From ACC

At The Cutting Edge of Developments in the Management of Hyperkalemia

Updates Abound in Hyperkalemia Management

Managing Complex Hypertension: What Every Physician Should Know

PCP Perspectives Clinical Considerations in Hyperkalemia

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Emerging Mechanisms in Glucose Metabolism

Resistant Hypertension

Iron Deficiency Anemia

The Parkinson's Disease Psychosis Journal Club

Bushinsky et al. Am J Nephrol 2016;44: (DOI: / )

Volume 89, Issue 6, Pages (June 2016)

Expert Perspectives on Hyperkalemia for the Specialist

HCV Protease Inhibitors in Clinical Practice

Is it Time for a Paradigm Change in HIV Management?

Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.

Exploring Emerging Treatments for Hyperkalemia

Expert Insights on Complex Clinical Cases of Edema

Iron Deficiency Anemia

Multidisciplinary Management of Hyperkalemia:

Hyperkalemia in the Hospital

The Evolving Treatment Landscape in Atopic Dermatitis

Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naïve patients with Chronic HCV GT 1, GT 4 and GT 6 Infection (C-CORAL): A Phase III Randomized.

Shifting Currents in Hyperkalemia Management 2015 in Review

Shifting Currents in Hyperkalemia Management 2015 in Review

Managing CKD-Associated Anemia in Challenging Patients

Battling the Flu: Latest Advances in the Influenza Treatment Arsenal

HCV Protease Inhibitors in Clinical Practice

Volume 90, Issue 3, Pages (September 2016)

HARMONIZE Trial design: Patients with hyperkalemia (K ≥5.1 mEq/L) were randomized in a 1:1:1:1.7 fashion to receive sodium zirconium cyclosilicate (ZS)

Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.

Deprescribing Calcium-Based Phosphorus Binders in Dialysis Patients

Post-Heart Failure Mortality

Assessing the Burden of Hyperkalemia

Breaking Down the Data in Hyperkalemia

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

AMD Therapy: Where Are We Now and Where Are We Going?

Assessing the Burden of Hyperkalemia

Binge Eating Disorder.

Uptitration of Medications in HF: Start Low but Aim High and Stay High

Anemia Explored.

Clinical Comparisons.

RAASi Enabling in the Modern Era

Case-Based Look at Hyperkalemia Identification, Diagnosis, and Management.

The causes and treatment of hyperkalemia across the continuum of kidney function and with kidney replacement therapies. The causes and treatment of hyperkalemia.

Potassium Situations Resolved

Presentation transcript:

At The Cutting Edge of Developments in the Management of Hyperkalemia

Program Goals

Recent Clinical Trial Data on Potassium Binders: Patiromer

OPAL-HK Phase 3 Pivotal Study Design

OPAL-HK Initial Treatment Phase

OPAL-HK: Phase 3 Study Part B Effect on Concomitant RAAS Inhibitor Therapy

Chronic Diuretic Therapy Does Not Impair the Effectiveness of Patiromer in Hyperkalemic Patients With CKD*

Use of Antihypertensive Medications and Hyperkalemia

Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Healthcare System: Study Design

PATHWAY-2 Optimal Treatment for Resistant Hypertension

Need for Potassium Binding Agents

Recent Clinical Trial Data on Potassium Binders: ZS-9

ZS-9*: Potassium Levels During the Acute and Maintenance Phase

Long-term Safety and Efficacy of ZS-9 in the Treatment of Hyperkalemia

Interim Safety Results of 52-week Trial of ZS-9 in Patients With Hyperkalemia

Implications of New and Emerging Potassium Binders in Clinical Practice

Hyperkalemia in Patients on Dialysis

Frequency of Hyperkalemia Events in Dialysis Patients

Serum Potassium and Mortality in Hemodialysis Patients

Developments in the Management of Hyperkalemia